The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients
Abstract
Purpose: To evaluate the predictive and prognostic value of peripheral blood cytokeratin-19 (CK-19) mRNA-positive cells in axillary lymph node–negative breast cancer patients. Patients and Methods: Peripheral blood was obtained from 167 node-negative breast cancer patients before the initiation of any systemic adjuvant therapy, and was analyzed for the presence of CK-19 mRNA-positive cells using a real time polymerase chain reaction assay. The association with known prognostic factors and the effect of CK-19 mRNA-positive cells on patients' prognosis was investigated. Results: CK-19 mRNA-positive cells were detected in the blood of 36 (21.6%) of the 167 patients. There was no correlation between the detection of CK-19 mRNA-positive cells in the peripheral blood and the various known pathologic and clinical prognostic factors; only overexpression of HER2 receptor (score 2+/3+) on the primary tumor was associated with a higher incidence of CK-19 mRNA-positive cell detection (P = .033). Multivariate analysis revealed that detection of peripheral blood CK-19 mRNA-positive cells was associated with early clinical relapse (P < .00001) and disease-related death (P = .008). Conclusion: Detection of peripheral-blood CK-19 mRNA-positive cells is an independent predictive and prognostic factor for reduced disease-free interval and overall survival, respectively, in node-negative breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Collett, D. (1991) · Springer eBooks · doi:10.1007/978-1-4899-4475-7 · Cited by 1,936
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Detection and Clinical Importance of Micrometastatic Disease
Pantel, K., Cote, R. J., & Fodstad, O. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.13.1113 · Cited by 493
Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., Kaul, S., & Bastert, G. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.22.1652 · Cited by 477
Lymph node micrometastases from breast carcinoma: Reviewing the dilemma
Dowlatshahi, K., Fan, M., Snider, H. C., & Habib, F. A. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1188::aid-cncr2>3.0.co;2-h · Cited by 430
Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394
Stathopoulou, A., Vlachonikolis, I., Mavroudis, D., Perraki, M., Kouroussis, C., Apostolaki, S., Malamos, N., Kakolyris, S., Kotsakis, A., Xenidis, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.135 · Cited by 335
Self-citationOutcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
Mansi, J. L., Gogas, H., Biss, J. M., Gazet, J.-C., Berger, U., & Coombes, R. C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10175-7 · Cited by 295
Wiedswang, G., Borgen, E., Kåresen, R., Kvalheim, G., Nesland, J. M., Qvist, H., Schlichting, E., Sauer, T., Janbu, J., Harbitz, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.009 · Cited by 284
Real-Time PCR Technology for Cancer Diagnostics
Bernard, P. S., & Wittwer, C. T. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1178 · Cited by 273
Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K.-W., & Schildberg, F. W. (1995) · Nature Medicine · doi:10.1038/nm1095-1035 · Cited by 252
Bland, K. I., Menck, H. R., Scott-Conner, C. E. H., Morrow, M., Winchester, D. J., & Winchester, D. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1262::aid-cncr28>3.0.co;2-2 · Cited by 216
Braun, S., Schlimok, G., Heumos, I., Schaller, G., Riethdorf, L., Riethmüller, G., & Pantel, K. (2001) · PubMed · Cited by 212
Global breast cancer mortality statistics
Mettlin, C. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.3.138 · Cited by 187
Bozionellou, V., Mavroudis, D., Perraki, M., Papadopoulos, S., Apostolaki, S., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E. S., & Georgoulias, V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0094 · Cited by 128
Self-citationDetection of circulating breast tumor cells by differential expression of marker genes.
Bosma, A. J., Weigelt, B., Lambrechts, A. C., Verhagen, O. J. H. M., Pruntel, R., Hart, A. A. M., Rodenhuis, S., & Veer, L. V. ‘. (2002) · PubMed · Cited by 96
p53 gene mutations are not required for early dissemination of cancer cells
Offner, S., Schmaus, W., Witter, K., Baretton, G. B., Schlimok, G., Passlick, B., Riethmüller, G., & Pantel, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6942 · Cited by 50
Cited by
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3663 · Cited by 510
Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2011) · Breast Cancer Research · doi:10.1186/bcr2896 · Cited by 377
Self-citationPierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Metadata
- Authors
- Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Bolonaki, I., Stathopoulou, A., Kalbakis, K., Androulakis, N., Kouroussis, C., Pallis, T., Christophylakis, C., Argyraki, K., Lianidou, E. S., Stathopoulos, S., Georgoulias, V., & Mavroudis, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-10
- Volume
- 24
- Issue
- 23
- Pages
- 3756-3762
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102949315
- Cited by
- 263
- References
- 27
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.